ilya zubkov

Steven Ralston

Bruce Jackson

Jason Kolbert

- VolitionRx Limited announced the pricing of an underwritten public offering of **11,550,000 shares of common stock** and **11,550,000 accompanying warrants** at a public offering price of **$0.52 per set of securities**, with **$0.01 allocated to each warrant**.  **[93314_0001477932-25-007544_vnrx_ex992.htm:0]** **[93314_0001477932-25-007544_vnrx_8k.htm:1]** 
- The offering closed on **October 14, 2025**, and is expected to generate approximately **$6.0 million in aggregate gross proceeds** before deductions, assuming no exercise of the underwriter's option.  **[93314_0001477932-25-007544_vnrx_ex992.htm:0]** **[93314_0001477932-25-007544_vnrx_8k.htm:2]** 
- The warrants have an exercise price of **$0.60 per share**, are exercisable immediately, and expire **five years from the issuance date**.  **[93314_0001477932-25-007544_vnrx_ex992.htm:0]** **[93314_0001477932-25-007544_vnrx_8k.htm:1]** **[93314_0001477932-25-007544_vnrx_ex41.htm:1]** 
- The company intends to use the net proceeds, estimated at approximately **$5.4 million**, for research and continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes, including potential strategic acquisitions.  **[93314_0001477932-25-007544_vnrx_ex991.htm:0]** **[93314_0001477932-25-007544_vnrx_ex992.htm:0]** **[93314_0001477932-25-007544_vnrx_8k.htm:1]** 
- Newbridge Securities Corporation acted as the sole book-running manager for the offering.  **[93314_0001477932-25-007544_vnrx_ex991.htm:0]** **[93314_0001477932-25-007544_vnrx_ex992.htm:0]** **[93314_0001477932-25-007544_vnrx_8k.htm:1]**

VolitionRx Limited Completes $6.0 Million Public Offering of Common Stock and Warrants

- VolitionRx Limited announced the pricing of an underwritten public offering of **11,550,000 shares of common stock** and accompanying warrants to purchase up to **11,550,000 shares of common stock**.  **[93314_20251010LN95114:0]** 
- The public offering price for each set of securities (one share and one warrant) is **$0.52**, with each warrant having an exercise price of **$0.60 per share** and expiring five years from issuance.  **[93314_20251010LN95114:0]** 
- The offering is expected to generate approximately **$6.0 million** in aggregate gross proceeds, excluding the exercise of any warrants and assuming no exercise of the underwriter's over-allotment option.  **[93314_20251010LN95114:0]** 
- Volition intends to use the net proceeds for **research, continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes**, including potential strategic acquisitions.  **[93314_20251010LN95114:0]** 
- The offering is anticipated to close on or about **October 14, 2025**.  **[93314_20251010LN95114:0]**

VolitionRx Prices Public Offering of Common Stock and Warrants

- VolitionRx Limited is proposing an **underwritten public offering** of its common stock and accompanying common stock purchase warrants.  **[93314_20251009LN94720:0]** 
- The company intends to grant the underwriter a 30-day option to purchase up to an additional **15%** of the number of shares of common stock and warrants offered.  **[93314_20251009LN94720:0]** 
- Net proceeds from the offering are intended for **research and continued product development, clinical studies, product commercialization, working capital**, and other general corporate purposes, including potential strategic acquisitions.  **[93314_20251009LN94720:0]** 
- **Newbridge Securities Corporation** is acting as the sole book-running manager for the proposed offering.  **[93314_20251009LN94720:0]**

VolitionRx Announces Proposed Public Offering of Common Stock and Warrants

- VolitionRx Limited has signed a co-marketing agreement with Hologic Diagenode for Volition's **Nu.Q® Discover service**.  **[93314_20250929LN85409:0]** 
- The partnership aims to greatly expand customer access to Volition's proprietary Nu.Q® Discover assays, which have an estimated total addressable market of **$200 million annually**.  **[93314_20250929LN85409:0]** **[93314_20250929LN85409:1]** 
- Hologic, which recorded revenues of over **$4 billion** in 2024, will co-market the service to its client base for an initial **one-year term**, with the potential for exclusive provider status if successful, to accelerate the expansion of Volition's services and grow revenues.  **[93314_20250929LN85409:0]** **[93314_20250929LN85409:1]**

VOLITIONRX (VNRX)